BioSpace.com News

Kadimastem Has Successfully Completed an IPO and Raised $5.5 Million USD

Mon, 10 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NESS ZIONA, Israel--(BUSINESS WIRE)--Kadimastem Ltd. (TASE:KDST), focusing on the development and industrial commercialization of products based on human embryonic stem cells, announced today the closing of...

CSRC Terminates IPO Applications of 15 China Life Science Companies

Thu, 06 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

June 6, 2013 -- The China Securities Regulatory Commission has terminated the IPO applications of fifteen China life science companies. To protect investors from inflated...

Kamada Ltd. Announces Pricing of Initial Public Offering

Wed, 05 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NESS ZIONA, Israel (May 31, 2013) Kamada Ltd. today announced the pricing of its initial public offering in the United States of 5582636 ordinary shares at a price to the public of $9.25 per ordinary share...

Kamada Ltd. Announces Closing of Initial Public Offering and Over-Allotment Option Exercise

Wed, 05 Jun 2013 12:00:00 AM GMT

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (Nasdaq and TASE: KMDA) today announced the closing of its initial public offering in the United States of 6,420,031 ordinary shares at a price to the public of $9.25 per ordinary share. All of the shares of common stock in the offering were offered by Kamada and include 837,395 shares issued pursuant to the over-allotment option granted to the underwriters...

Epizyme Prices IPO at $15 Per Share, Begins Trading Today

Fri, 31 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Epizyme, Inc. Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., May 30, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc...

Evoke Pharma, Inc. Files $24 Million IPO

Fri, 31 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Evoke Pharma (NASDAQ: EVOK) filed a $24 million IPO on form S-1 with the SEC this afternoon. The company plans to list its shares on the NASDAQ under the trading symbol "EVOK." Aegis Capital is the lone underwriter...

Portola Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Over-Allotment Option Exercise

Thu, 30 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, CA--(Marketwired - May 28, 2013) - Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) announced...

Alcobra Raises $25 Million on NASDAQ

Wed, 29 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ADHD co Alcobra raises $25m on Nasdaq

/Tali Tsipori and Gali Weinreb, Globes/ -- Alcobra Pharmaceuticals Inc., which is developing a treatment for attention deficit hyperactivity...

Ironwood Pharmaceuticals Prices $136.5 Million Stock Offering

Wed, 22 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Ironwood Pharmaceuticals Prices Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (IRWD) today announced the pricing of...

INSYS Therapeutics Completes $37 Million IPO to Back Medical Marijuana Drug

Tue, 21 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Insys Therapeutics Inc. has completed its $36.8 million initial public offering to help bolster sales of its medical marijuana drug one of a handful of Arizona IPOs within the past seven months. The resurgence...

Ambit Biosciences Cuts IPO Price

Thu, 16 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Ambit Biosciences Announces Pricing of Initial Public Offering

SAN DIEGO, May 16, 2013 /PRNewswire/ -- Ambit Biosciences Corporation today announced the...

Quintiles, Inc.'s $947.4M IPO to Spawn a New Billionaire

Fri, 10 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Quintiles today announced the pricing of its initial public offering of 23,684,210 shares of its common stock at a price to the public of $40.00 per share. The...

Quintiles, Inc. Celebrates IPO on the New York Stock Exchange

Fri, 10 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Research Triangle Park, N.C.-based Quintiles, a leading global provider of biopharmaceutical development and commercial outsourcing services, visited the New York Stock Exchange ...

Receptos Announces Pricing of Initial Public Offering of Common Stock

Thu, 09 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, May 8, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the...

San Diego's Receptos, Ambit Biosciences, Get Ready for IPO Debuts

Tue, 07 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

San Diego-based Receptos, a biotech developing new treatments for immune disorders, is among 13 IPOs expected to go public this week, according to Renaissance Capital, a financial firm in Greenwich, CT, that...

INSYS Therapeutics Announces Closing of IPO and Exercise of Underwriters' Over-Allotment Option

Tue, 07 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PHOENIX, AZ--(Marketwired - May 07, 2013) - Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical...

INSYS Therapeutics Announces Pricing of IPO

Thu, 02 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PHOENIX, AZ--(Marketwired - May 02, 2013) - Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical...

TPG-Backed Quintiles, Inc. Outlines $790 Million Price in IPO

Fri, 26 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Quintiles Transnational Holdings Inc., the biggest provider of testing services to drugmakers, filed to raise about $790 million in a U.S. initial public offering. The company and its shareholders, including...

Omthera Pharmaceuticals, Inc. Prices Upsized IPO Below the Range at $8

Thu, 11 Apr 2013 12:00:00 AM GMT

PRINCETON, N.J., April 11, 2013 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, today announced the pricing of its initial public offering of 8,000,000 shares of its common stock at

Harvard Apparatus Postpones $19 Million IPO

Wed, 10 Apr 2013 12:00:00 AM GMT

HOLLISTON, Mass., April 9, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that the planned initial public offering by its wholly-owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, Inc., or HART...

Chimerix, Inc. Sets Terms for $85 Million IPO

Tue, 02 Apr 2013 12:00:00 AM GMT

Chimerix, a biopharmaceutical company developing oral antiviral therapeutics for CMV, announced terms for its IPO on Monday. The Durham, NC-based company plans to raise $85 million by offering 6.1 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Chimerix would command a market value of $325 million.

Enanta Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option

Wed, 27 Mar 2013 12:00:00 AM GMT

WATERTOWN, Mass.--March 26, 2013--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced the closing of its initial public offering of 4,600,000 shares of its common stock at a price to the public of $14.00 per share, which includes the exercise in full by the underwriters...

Enanta Pharmaceuticals, Inc. Raises $56 Million in IPO

Thu, 21 Mar 2013 12:00:00 AM GMT

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $14.00 per share. The shares of Enantas common stock will trade...

Zoetis Closes Initial Public Offering

Thu, 07 Feb 2013 12:00:00 AM GMT

MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE:ZTS), formerly the animal health business unit of Pfizer Inc., today announced the closing of its previously announced initial public offering. The offering of 99,015,000 shares of its Class A common stock included 12,915,000 shares of Class A common stock that were sold pursuant to the underwriters option to purchase additional shares, which was exercised...

KaloBios Pharmaceuticals, Inc. Completes Initial Public Offering

Thu, 07 Feb 2013 12:00:00 AM GMT

SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced the completion of its initial public offering of 8,750,000 shares of common stock at $8.00 per share. Gross proceeds from the offering were

Pfizer Inc.'s Zoetis Hauls in $2.24 Billion in IPO

Fri, 01 Feb 2013 12:00:00 AM GMT

Zoetis Inc., the animal-health company owned by Pfizer (PFE) Inc., raised $2.24 billion in its initial public offering, pricing the shares above the marketed price range. Zoetis sold 86.1 million shares at $26 each, according to a statement yesterday, after offering them for $22 to $25. Pfizer offered about 17 percent of Zoetis in the IPO, the biggest in the U.S. since Facebook Inc.s last year. The...

Stemline Therapeutics, Inc. Announces Closing of Initial Public Offering

Fri, 01 Feb 2013 12:00:00 AM GMT

NEW YORK, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today the closing of its previously announced initial public offering of 3,815,291 shares of common stock, including the exercise in full of the over-allotment option covering...

Stemline Therapeutics, Inc. Rises in Its Market Debut as First Biotech IPO of 2013

Wed, 30 Jan 2013 12:00:00 AM GMT

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics, announced the pricing of initial public offering of 3.318 million common shares at $10.00 per share, the low end of the estimated range. The offering is expected to close on January 31, 2013. In an amended regulatory filing with the U.S. Securities and Exchange Commission on January 8, the company...

KaloBios Pharmaceuticals, Inc. on Path Toward $50 Million IPO

Mon, 28 Jan 2013 12:00:00 AM GMT

KaloBios Pharmaceuticals Inc. has priced its initial public offering in a $12 to $14 per share range, translating at its midpoint into a fundraising of $50 million. The South San Francisco company, which develops so-called Humaneered monoclonal antibodies to treat respiratory diseases and cancer, plans to sell 3.85 million shares. Its stock would be listed on the NASDAQ under the symbol "KBIO." Leerink...

Vantiv Succeeds With IPO, Begins Rapid Acquisitions

Fri, 28 Dec 2012 12:00:00 AM GMT

After a long, long drought, Greater Cincinnati finally got back into the IPO game in 2012. Vantiv, the Symmes Township-based electronic payment processor, in March completed its initial public offering, selling $575 million in stock. Vantiv itself sold $500 million in the offering, while existing shareholders sold the rest in the over-allotment for underwriters to fill extra orders.

Cancer Drug Spinoff of Australian Company, Audeo Oncology Inc. Preps $49 Million IPO

Mon, 10 Dec 2012 12:00:00 AM GMT

An Australian import to San Francisco plans to raise $49 million in an initial public offering to fuel late-stage development of its experimental cancer-targeting drug. Audeo Oncology Inc., incorporated in June as part of a reorganization of the publicly traded Australian company Alchemia Ltd., priced its IPO of 3.25 million shares at $14-16 per share. It will trade starting next week on the NASDAQ...

Puma Biotechnology Raises $138 Million in Public Offering of Common Stock

Fri, 26 Oct 2012 12:00:00 AM GMT

Puma Biotechnology, Inc. | Jobs at Puma Biotechnology, Inc.

Puma Biotechnology, Inc. (NYS: PBYI) , a development stage biopharmaceutical company, announced...

BioIndustry Association Release: Latest French Biotech IPO Demonstrates the Potential of Citizens' Innovation Funds

Thu, 25 Oct 2012 12:00:00 AM GMT

25 October 2012 -- A French biotech company supported by funds raised through a scheme the BIA has proposed is introduced in the UK, has announced the raising of 14.2 million in its Initial Public Offering (IPO) on the Euronext.

Funds raised through the Fonds Commun de Placement dans I'Innovation (FCPI), on which the BIA has modelled its Citizens' Innovation Funds proposal launched last...

MannKind Corporation Prices Offering at 23 Pct Discount

Thu, 18 Oct 2012 12:00:00 AM GMT

VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD) today announced the pricing of an underwritten public offering of 40,000,000 shares of its common stock, together with warrants to purchase up to an aggregate of 30,000,000 shares of its common stock. Each share of common stock is being sold together with a warrant for a combined purchase price of $2.00. Each warrant entitles the...

ImmunoCellular Therapeutics, Ltd Announces Pricing of its Previously Announced Public Offering of Common Stock and Warrants

Thu, 18 Oct 2012 12:00:00 AM GMT

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (ImmunoCellular) (NYSE MKT: IMUC) today announced that it has priced an underwritten public offering of an aggregate of 10,000,000 shares of its Common Stock, at a price to the public of $2.10 per share, and warrants to purchase up to an aggregate of 4,500,000 shares of Common Stock. The net offering proceeds to ImmunoCellular from this...

Anacor Pharmaceuticals, Inc. Prices $24 Million Public Offering of Common Stock

Thu, 18 Oct 2012 12:00:00 AM GMT

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $6.00 per share for gross proceeds of $24 million. Anacor has also granted the underwriter a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the...

Kythera Biopharmaceuticals Announces Closing of Initial Public Offering and Exercise of Underwriters??? Over-Allotment Option

Tue, 16 Oct 2012 12:00:00 AM GMT

LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced the closing of its initial public offering of 5,060,000 shares of its common stock at an initial public offering price of $16.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 660,000 additional shares of common stock. KYTHERA Biopharmaceuticals common...

Intercept Pharmaceuticals, Kythera Biopharmaceuticals Take Off in IPOs

Fri, 12 Oct 2012 12:00:00 AM GMT

A pair of biopharmaceutical IPOs rose sharply in early Thursday trading, gaining ground after each company upped the number of shares they brough to market. Kythera Biopharmaceuticals Inc.'s (KYTH) rose $3.79, or 24%, to close at $19.79. The stock opened at $18.49, up 16% from the the $16 offer price, and continued to rise during Thursday's session.

Isis Pharmaceuticals, Inc. Investment in Regulus Therapeutics, Inc. Valued at $28 Million at Completion of Initial Public Offering

Thu, 11 Oct 2012 12:00:00 AM GMT

CARLSBAD, Calif., Oct. 11, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Regulus Therapeutics Inc. recently priced its initial public offering of 11,250,000 shares of Regulus common stock at $4.00 per share. Isis purchased $3 million of Regulus common stock at the...

Intercept Pharmaceuticals Announces Pricing of Initial Public Offering

Thu, 11 Oct 2012 12:00:00 AM GMT

NEW YORK, Oct. 11, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All...

Kythera Biopharmaceuticals Announces Pricing of Initial Public Offering

Thu, 11 Oct 2012 12:00:00 AM GMT

LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced the pricing of its initial public offering of 4,400,000 shares of its common stock at a price to the public of $16.00 per share. The shares of KYTHERA's common stock will trade on the NASDAQ Global Select Market under the symbol "KYTH." All of the shares of common stock are being offered by KYTHERA. In addition...

Fosun Pharma's Hong Kong IPO Set to Raise $600 Million

Fri, 05 Oct 2012 12:00:00 AM GMT

by Richard Daverman, PhD

October 5, 2012 -- Fosun Pharmas long-in-the-works IPO on the Hong Kong exchange is scheduled to take place this month, raising a diminished $600 million. The company received regulatory approval for the offering five months ago, but market conditions have held the transaction back until now and caused the company to drop the projected take from $800 million. There...

Regulus Therapeutics, Inc. Announces Pricing of Initial Public Offering

Thu, 04 Oct 2012 12:00:00 AM GMT

LA JOLLA, Calif., Oct. 4, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the pricing of its initial public offering of 11,250,000 shares of its common stock at ...

Kythera Biopharmaceuticals Prices IPO

Fri, 28 Sep 2012 12:00:00 AM GMT

Kythera Biopharmaceuticals Inc. has set a pricing range for its planned initial public offering of 4 million shares at $14 to $16 per share.

The Calabasas-based company, which is in clinical stages for developing a drug to treat chin fat, is seeking to list on the Nasdaq Global Market under the ticker symbol KYTH.

The company filed a registration statement with the Securities and...

GlobeImmune, Inc. Offers IPO Details

Thu, 06 Sep 2012 12:00:00 AM GMT

GlobeImmune Inc. intends to offer 5 million shares at $11 to $13 in its planned initial public offering, it indicated in a securities filing Wednesday.

The Louisville-based pharmaceutical company is working on drugs to treat infectious diseases and cancers. GlobeImmune has said it plans to use proceeds from the IPO to fund clinical trials and for potential manufacturing.

GlobeImmune...

China National Biotech Group Approved for $1.6 Billion Hong Kong IPO

Thu, 06 Sep 2012 12:00:00 AM GMT

by Richard Daverman, PhD

September 6, 2012 -- China National Biotec Group, a unit of China's sprawling state-owned pharmaceutical giant, Sinopharm Group, will seek to raise up to 10 billion RMB ($1.6 billion) in a Hong Kong IPO. The company was given an OK to stage its previously announced IPO by Hong Kongs environment ministry today. It still needs the blessing of the China Securities Regulatory...

The Week in Review: Tigermed and Complete IPOs

Tue, 21 Aug 2012 12:00:00 AM GMT

by Richard Daverman, PhD

August 18, 2012 -- Hangzhou Tigermed Consulting, a clinical-stage CRO, staged an $80 million IPO on Shenzhens ChiNext exchange; Hainan Shuangcheng Pharma made its public company debut on the Shenzhen main board, raising $94 million; two China medical research organizations will work with the National University of Ireland Galway to develop polymer delivery systems...

Tigermed Completes $80 Million IPO on the Exchange

Mon, 20 Aug 2012 12:00:00 AM GMT

by Richard Daverman, PhD

August 17, 2012 -- Hangzhou Tigermed Consulting Co., a clinical-stage CRO, staged its IPO today on Shenzhens ChiNext exchange. The IPO, which constitutes 25% of the companys outstanding stock, placed 13.40 million shares in investors hands at a price of 37.88 RMB, a price/earnings ratio of 44. The transaction raised 508 million RMB ($80 million) for the company...

Fluidigm Corporation Prices $52.2 Million Public Offering of Common Stock

Thu, 16 Aug 2012 12:00:00 AM GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation (NASDAQ: FLDM), a supplier of microfluidic systems for growth markets in the life science and agricultural biotechnology industries, today announced the pricing of an underwritten public offering of 3,660,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of $52.2 million. The net proceeds...

Hainan Shuangcheng Pharma Stages $94 Million IPO in Shenzhen

Wed, 15 Aug 2012 12:00:00 AM GMT

by Richard Daverman, PhD

August 15, 2012 -- Hainan Shuangcheng Pharmaceuticals debuted on the Shenzhen exchange last week, raising 600 million RMB ($94 million) in its IPO offering. Founded in 2000, Hainan Shuangcheng Pharma is a high-tech enterprise specializing in chemosynthetic polypeptide medicines. The offering was priced at 20 RMB, and the companys shares have moved up to 25.2 RMB...

Stemline Therapeutics, Inc. Postpones IPO

Thu, 09 Aug 2012 12:00:00 AM GMT

Stemline Therapeutics, a biotech developing treatments that target cancer stem cells and tumor bulk, postponed its IPO on Tuesday. The New York, NY-based company had been planning to raise $42 million at a price range of $11 to $13. RBC Capital Markets, Oppenheimer & Co. were set to be the joint bookrunners on the deal.

Hyperion Therapeutics Completes Initial Public Offering and Announces Exercise of Underwriters' Over-Allotment Option

Wed, 01 Aug 2012 12:00:00 AM GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hyperion Therapeutics, Inc. (NASDAQ:HPTX) announced today the completion of its initial public offering of 5,000,000 shares of common stock. In addition, the underwriters of its initial public offering exercised their over-allotment option in full and purchased an additional 750,000 shares of common stock. All of such shares were sold by Hyperion Therapeutics...

Idenix Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Wed, 01 Aug 2012 12:00:00 AM GMT

CAMBRIDGE, Mass., July 31, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has commenced an underwritten registered public offering of $150 million of its common stock. All of these shares are being sold by Idenix.

Hyperion Therapeutics Prices IPO at $10.00, Below the Range Expected

Thu, 26 Jul 2012 12:00:00 AM GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hyperion Therapeutics, Inc. (NASDAQ:HPTX) announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Hyperion. In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares...

Durata Therapeutics, Inc. Closes Initial Public Offering

Wed, 25 Jul 2012 12:00:00 AM GMT

MORRISTOWN, N.J.--(BUSINESS WIRE)-- Durata Therapeutics (DRTX) today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering...

Zogenix, Inc. Prices Public Offering of Common Stock and Warrants to Purchase Common Stock

Tue, 24 Jul 2012 12:00:00 AM GMT

SAN DIEGO, July 24, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it has priced an underwritten public offering of 32,500,000 units. Each unit consists of one share of common stock and a warrant to purchase 0.45 of a share of common stock, at a...

Durata Therapeutics, Inc. Prices $68 Million IPO

Thu, 19 Jul 2012 12:00:00 AM GMT

MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics today announced the pricing of its initial public offering of 7,500,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts. The shares are scheduled to begin trading on the NASDAQ Global Market on July 19, 2012 under the ticker symbol DRTX."

In addition, the underwriters have an option...

Tesaro, Inc. Announces Pricing of Initial Public Offering

Thu, 28 Jun 2012 12:00:00 AM GMT

WALTHAM, Mass., June 27, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $13.50 per share. The shares of TESARO's common stock have been approved for listing on the NASDAQ Global Select Market and are expected to begin trading tomorrow, June 28, 2012, under the symbol "TSRO." All of...

Tesaro, Inc. Sets Terms for $81 Million US IPO

Wed, 20 Jun 2012 12:00:00 AM GMT

Tesaro, a biotech focused on the treatment of chemotherapy-induced symptoms, announced terms for its IPO on Tuesday. The Waltham, MA-based company plans to raise $81 million by offering 6.0 million shares at a price range of $12 to $15. At the midpoint of the proposed range, Tesaro would command a market value of $360 million. The company's lead product candidate, rolapitant, is in Phase 3 trials...

Cathay Industrial Biotech Withdraws $90 Million IPO

Wed, 13 Jun 2012 12:00:00 AM GMT

Cathay Industrial Biotech, a Chinese producer of biobutanol and LCDAs used in chemical and fuel markets, withdrew its plans for an initial public offering on Monday. The Shanghai, China-based company, which was founded in 1997, originally postponed its IPO in August 2011. The company was planning on raising $90 million by offering 6.9 million shares at a price range of $12 to $14. Morgan Stanley, Deutsche...

After Successful IPO, Verastem, Inc. Tries to Deliver on Promise

Thu, 24 May 2012 12:00:00 AM GMT

Two-year-old Verastem Inc., which raised $55 million in an initial public offering in late January, was one of the first biotechnology start-ups in years to take its shares public before its drugs had entered clinical trials, a coup in an era of skeptical investors. Four months later, as executives on Tuesday remotely rang the opening bell on the Nasdaq exchange from their research lab in Cambridge...

Cancer Genetics, Inc. Delays IPO to Avoid Faceoff with

Mon, 21 May 2012 12:00:00 AM GMT

Cancer Genetics (CGIX) operates in a completely different space than Facebook (FB), and while other companies are postponing their IPOs or withdrawing them all together, this name is still looking to start trading this week. It's possible that underwriters think because the offering is so small, there will still be plenty of available capital to participate in the IPO. Cancer Genetics is pricing ...

China National Biotech Group to Raise $1.6 Billion in Hong Kong IPO

Fri, 18 May 2012 12:00:00 AM GMT

by Richard Daverman, PhD

May 18, 2012 -- China National Biotech Group (CNBG) expects to raise up to 10 billion RMB ($1.6 billion) in a Hong Kong IPO, according to sources. CNBH is one of many subsidiaries of the sprawling state-owned China National Pharmaceutical Group Corp (Sinopharm). Last November, Zhiping Song, Chairman of the parent company, said the IPO would take place in the first...

Rib-X Pharmaceuticals, Inc. Postpones IPO After Slashing Price by 50 Pct

Fri, 11 May 2012 12:00:00 AM GMT

Rib-X Pharmaceuticals Inc., an antibiotic developer based in New Haven, Conn., on Wednesday morning postponed its anticipated IPO only one day after it cut the price about 50 percent, according to information from the Nasdaq OMX Group Inc. citing Renaissance Capital. The company did not return calls for comment. A source close to the company confirmed that the IPO was postponed because of market conditions...

Dynavax Technologies Corporation Sinks on Discounted Offering, CEO Exit

Wed, 09 May 2012 12:00:00 AM GMT

May 9 (Reuters) - Shares of Dynavax Technologies Corp , which priced its public offering at a steep discount, fell as much as 22 percent a day after the biopharmaceutical company said its chief executive intends to step down.

Supernus Pharmaceuticals Prices IPO at $5, Raising $50 Million

Tue, 01 May 2012 12:00:00 AM GMT

ROCKVILLE, Md., Apr 30, 2012 (GlobeNewswire via COMTEX) -- Supernus Pharmaceuticals, Inc. (the "Company") today announced the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The Company's shares are expected to begin trading on The NASDAQ Global Market on Tuesday, May 1, 2012 under the trading symbol "SUPN." The underwriters have a 30 day option to purchase...

Fosun Pharma Given OK for Hong Kong IPO

Thu, 12 Apr 2012 12:00:00 AM GMT

April 11, 2012 --Shanghai Fosun Pharma has been given regulatory approval to issue 547 million H shares in a Hong Kong IPO. The transaction is expected to occur in the second quarter. Because the company's Shanghai stock price has slipped lower in the last six months, the offering has also dropped in size from the original announcement: it is now expected in a range between $600 million and $800 million...

Supernus Pharmaceuticals Sets Terms for $75 Million US IPO

Thu, 12 Apr 2012 12:00:00 AM GMT

Washington Business Journal by Bill Flook, Staff Reporter

Supernus Pharmaceuticals Inc., which filed for an initial public offering more than a year ago, said Wednesday it expects to sell 5.8 million shares at an estimated price of $12 to $14 apiece.

In a Securities and Exchange Commission filing, the Rockville biotech estimated it would raise $66.4 million in net proceeds through...

Shares of Merrimack Pharmaceuticals Inc. Stock Drops Post - IPO

Fri, 30 Mar 2012 12:00:00 AM GMT

Boston Business Journal by Julie M. Donnelly, Reporter

Merrimack Pharmaceuticals Inc. (Nasdaq: MACK) , went public Thursday, debuting at $7 per share but falling by 14 percent by the afternoon. The Cambridge, Mass-based company announced it would delay its IPO in February, and earlier this month said it would lower its sights on how much it planned to raise in the IPO, to $100 million from...

Merrimack Pharmaceuticals Inc. Sets New IPO Terms, Aiming to Raise Less $

Wed, 28 Mar 2012 12:00:00 AM GMT

Boston Business Journal by Kyle Alspach, VC Editor

Merrimack Pharmaceuticals has set new terms for its initial public offering of stock, after postponing its IPO plans in February, IPO tracker Renaissance Capital reported.

The Cambridge-based biotech, which is developing several potential treatments for cancer, had previously sought to raise up to $166 million through an IPO, selling...

Pfizer Inc. Mulls $3 Billion Partial IPO for Animal Healthcare Unit: Report

Tue, 21 Feb 2012 12:00:00 AM GMT

Pfizer plans to raise about $3 billion this year through a part-flotation of its animal health division, the Financial Times reported on Sunday. The pharmaceuticals group [PFE 21.18 -0.01 (-0.05%) ] has been in discussions with bankers over an initial public offering that would look to place up to 19.9 percent of the units shares in the autumn, according to people familiar with the talks, cited...

Beijing Leadman Biochemistry Completes ChiNext IPO

Thu, 16 Feb 2012 12:00:00 AM GMT

February 16, 2012 -- Beijing Leadman Biochemistry completed an IPO on the Shenzhens ChiNext exchange, raising almost 500 million RMB ($79 million). The company issued 38.4 million shares at a price of 13 RMB. Leadman produces IVD reagents, medical devices, and chemical raw materials. The issue price reflects a PE ratio of 37. In its first open market session, Leadman rose even higher, climbing 2...

ChemoCentryx, Inc. Completes IPO

Tue, 14 Feb 2012 12:00:00 AM GMT

MOUNTAIN VIEW, Calif., Feb. 13, 2012 /PRNewswire/ -- ChemoCentryx, Inc. (NASDAQ: CCXI) announced today the completion of its initial public offering of 4,500,000 shares of common stock. In addition, the underwriters of its initial public offering exercised their over-allotment option in full and purchased an additional 675,000 shares of common stock. All of such...

Chinese Drugmaker IPO Protested Over Bear Bile

Mon, 13 Feb 2012 12:00:00 AM GMT

Just as major drugmakers such as GlaxoSmithKline express more interest in traditional Chinese medicine (see this), some practices are generating sustained protests. One example is using bile from captive black bears to make pharmaceuticals for treating the liver and eyes. To thwart Guizhentang Pharmaceuticals, which reportedly keeps nearly 500 bears on its farms, from trading its stock publicly, animal...

Merrimack Pharmaceuticals Inc. Scraps IPO Plans

Thu, 02 Feb 2012 12:00:00 AM GMT

Boston Business Journal by Julie M. Donnelly, Reporter

Merrimack Pharmaceuticals has postponed its $166 million IPO, originally scheduled for this week, according to IPO tracker Renaissance Capital, due to poor market conditions.

The Cambridge, Mass-based company, which is developing potential treatments for cancer, planned to sell 16,666,667 shares of common stock at an estimated...

Verastem, Inc. Bucks the Trend, Raises $55 Million in IPO

Fri, 27 Jan 2012 12:00:00 AM GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold...

ChemoCentryx, Inc. Sets $14-$16 Range for IPO

Thu, 26 Jan 2012 12:00:00 AM GMT

ChemoCentryx Inc. on Monday set a target range of $14 to $16 for its initial public offering.

The target at the top of the range would bring in $64 million, slightly less than the $69 million the Mountain View biopharmaceutical company filed for back in October.

ChemoCentryx, focused on the treatment of autoimmune diseases, inflammatory disorders and cancer, said it plans to offer...

Xizang Haisco Pharma Completes $127 Million IPO

Tue, 17 Jan 2012 12:00:00 AM GMT

January 17, 2012 -- Xizang Haisco Pharmaceutical Group, which produces TCM drug formulations and active pharmaceutical ingredients, completed a $127 million IPO on Shenzhens Small and Medium-Sized Enterprises Board. The company, located in Chinas autonomous Tibet region, is the 11th Tibetan entity to become publicly owned. CITIC Securities was the lead underwriter. More details....

Stock...

Verastem, Inc. 4.5 Million-Share IPO Seen Pricing at $9-$11 a Piece

Tue, 17 Jan 2012 12:00:00 AM GMT

Cancer drug developer Verastem Inc. expects its initial public offering of 4.5 million shares to price between $9 and $11 apiece.

Clovis Oncology Raises $130 Million in IPO

Wed, 16 Nov 2011 12:00:00 AM GMT

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (Nasdaq: CLVS) announced today the pricing of its initial public offering of 10,000,000 shares of its common stock at $13.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Clovis Oncology. In addition, the underwriters have a 30-day option to purchase up to an additional 1,500,000 shares of...